University Health Network

Biologics and methotrexate (MTX) treatments for psoriatic arthritis (PsA) affect serum CXCL10, MMP3, S100A8, ACP5, and CCL2 levels, which may serve as biomarkers for predicting treatment response. High baseline levels of ACP5 and low MMP3 were predictive of DAPSA response, while high CXCL10 and S100A8 levels predicted PASI response. MMP3, S100A8, ACP5, and CXCL10 show potential as serum biomarkers for PsA treatment response.

Phase 3 trial data showed the pozelimab and cemdisiran (poze-cemdi) combination achieved greater control of intravascular hemolysis in PNH patients compared to ravulizumab, with 96% achieving adequate LDH control versus 80% with ravulizumab. Poze-cemdi also demonstrated complete, uninterrupted inhibition of terminal complement, offering potential for less frequent, subcutaneous administration.

Rivoceranib plus camrelizumab showed improved survival over sorafenib in advanced HCC, with median OS of 23.8 vs 15.2 months and PFS of 5.6 vs 3.7 months. The combination's safety profile supports its use as a first-line treatment, despite FDA concerns over manufacturing site deficiencies.

Canada's health care system, once a source of national pride, is now in crisis due to government mismanagement, lack of transparency, and insufficient funding. Overworked and underpaid medical professionals face outdated facilities and bureaucratic inefficiencies, leading to shortages and demoralization. The article argues for structural reforms, including private-sector involvement, to address the system's deep-rooted issues and improve care quality and efficiency.